PHIO PHARMACEUTICALS CORP. Operating Lease, Right-of-Use Asset, Amortization Expense
PHIO PHARMACEUTICALS CORP. (PHIO) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-03-05
- PHIO PHARMACEUTICALS CORP. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $0.00.
- PHIO PHARMACEUTICALS CORP. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $0.00.
- PHIO PHARMACEUTICALS CORP. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $0.00.
- PHIO PHARMACEUTICALS CORP. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- PHIO PHARMACEUTICALS CORP. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- PHIO PHARMACEUTICALS CORP. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $33.00K, a 74.22% decline from fiscal 2023.
- PHIO PHARMACEUTICALS CORP. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $128.00K, a 4.92% increase from fiscal 2022.
- PHIO PHARMACEUTICALS CORP. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $122.00K, a 4.27% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $0.00 10-K · filed 2026-03-05 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 4 quarters · filed 2026-03-05 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $0.00 derived: sum of 4 quarters · filed 2026-03-05 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $0.00 derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $33.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $33.00K 10-Q · filed 2025-11-13 | $66.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $33.00K 10-Q · filed 2025-08-14 | $66.00K derived: sum of 3 quarters · filed 2025-08-14 | $98.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $33.00K 10-Q · filed 2025-05-15 | $66.00K derived: sum of 2 quarters · filed 2025-05-15 | $98.00K derived: sum of 3 quarters · filed 2025-05-15 | $130.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $65.00K derived: sum of 2 quarters · filed 2025-03-31 | $97.00K derived: sum of 3 quarters · filed 2025-03-31 | $128.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $32.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $64.00K derived: sum of 2 quarters · filed 2024-11-14 | $95.00K 10-Q · filed 2024-11-14 | $126.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $63.00K 10-Q · filed 2024-08-14 | $94.00K derived: sum of 3 quarters · filed 2024-08-14 | $125.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $31.00K 10-Q · filed 2024-05-09 | $62.00K derived: sum of 2 quarters · filed 2024-05-09 | $93.00K derived: sum of 3 quarters · filed 2024-05-09 | $123.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $62.00K derived: sum of 2 quarters · filed 2024-04-01 | $92.00K derived: sum of 3 quarters · filed 2024-04-01 | $122.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | $31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $61.00K derived: sum of 2 quarters · filed 2023-11-09 | $91.00K 10-Q · filed 2023-11-09 | $121.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $30.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $60.00K 10-Q · filed 2023-08-10 | $90.00K derived: sum of 3 quarters · filed 2023-08-10 | $119.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $30.00K 10-Q · filed 2023-05-11 | $60.00K derived: sum of 2 quarters · filed 2023-05-11 | $89.00K derived: sum of 3 quarters · filed 2023-05-11 | $118.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $59.00K derived: sum of 2 quarters · filed 2023-03-22 | $88.00K derived: sum of 3 quarters · filed 2023-03-22 | $117.00K 10-K · filed 2023-03-22 |
| 2021-09-30 | $29.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $58.00K derived: sum of 2 quarters · filed 2022-11-10 | $87.00K 10-Q · filed 2022-11-10 | $115.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $29.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $58.00K 10-Q · filed 2022-08-11 | $86.00K derived: sum of 3 quarters · filed 2022-08-11 | $114.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $29.00K 10-Q · filed 2022-05-12 | $57.00K derived: sum of 2 quarters · filed 2022-05-12 | $85.00K derived: sum of 3 quarters · filed 2022-05-12 | $113.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $56.00K derived: sum of 2 quarters · filed 2022-03-22 | $84.00K derived: sum of 3 quarters · filed 2022-03-22 | $111.00K 10-K · filed 2022-03-22 |
| 2020-09-30 | $28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $56.00K derived: sum of 2 quarters · filed 2021-11-10 | $83.00K 10-Q · filed 2021-11-10 | $110.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $28.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $55.00K 10-Q · filed 2021-08-12 | $82.00K derived: sum of 3 quarters · filed 2021-08-12 | $109.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $27.00K 10-Q · filed 2021-05-13 | $54.00K derived: sum of 2 quarters · filed 2021-05-13 | $81.00K derived: sum of 3 quarters · filed 2021-05-13 | $108.00K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $54.00K derived: sum of 2 quarters · filed 2021-03-25 | $81.00K derived: sum of 3 quarters · filed 2021-03-25 | $109.00K 10-K · filed 2021-03-25 |
| 2019-09-30 | $27.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $54.00K derived: sum of 2 quarters · filed 2020-11-10 | $82.00K 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $55.00K 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $28.00K 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |